Toxicological Sciences 56, 18-25 (2000)
Copyright © 2000 by the Society of Toxicology
Biliary and Urinary Excretion of Inorganic Arsenic: Monomethylarsonous Acid as a Major Biliary Metabolite in Rats
Department of Pharmacology, University Medical School of Pécs, Szigeti út 12, H-7643 Pécs, Hungary
In rats exposed to arsenite (AsIII) or arsenate (AsV), the biliary excretion of arsenic depends completely on availability of hepatic glutathione, suggesting that both AsIII and AsV are transported into bile in thiol-reactive trivalent forms (Gyurasics et al. [1991], Biochem. Pharmacol. 42, 465–468). To test this hypothesis, the bile and urine of bile duct-cannulated rats injected with AsIII or AsV (50 µmol/kg, iv) were collected periodically for 2 h and analyzed for arsenic metabolites by HPLC-hydride generation-atomic fluorescence spectrometry. Arsenic was excreted predominantly into bile in AsIII-injected rats, but the urine was the main route of excretion in AsV-exposed rats. Injected AsIII was excreted in urine practically unchanged, whereas both AsV and AsIII appeared in urine after administration of AsV. Irrespective of the arsenical administered, the bile contained 2 main arsenic species, namely AsIII and a hitherto unidentified metabolite. Formation of this metabolite could be prevented by pretreatment of the rats with the methylation inhibitor periodate-oxidized adenosine, indicating that it is a methylated arsenic compound. This metabolite could be converted in vitro into monomethylarsonic acid (MMAsV) by oxidation, whereas synthetic MMAsV could be converted into the unknown metabolite by reduction. Consequently, this biliary metabolite of both AsIII and AsV is monomethylarsonous acid (MMAsIII), a long-hypothesized, but never identified, intermediate in the biotransformation of AsIII and AsV. Although MMAsIII is thought to be formed from an oxidized precursor, rats injected with MMAsV did not excrete MMAsIII. In summary, the inorganic arsenicals investigated are transported into bile exclusively in trivalent forms, namely as AsIII and MMAsIII, but are excreted in urine in both tri- and pentavalent forms. Identification of MMAsIII is signified by the fact that this metabolite is more toxic than AsIII and AsV and thus formation of MMAsIII represents toxification of inorganic arsenic.
Key Words: arsenic; monomethylarsonous acid; biliary excretion; methylation; urinary excretion.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Yuan, X. Lu, N. Oro, Z. Wang, Y. Xia, T. J. Wade, J. Mumford, and X. C. Le Arsenic Speciation Analysis in Human Saliva Clin. Chem., January 1, 2008; 54(1): 163 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Nemeti and Z. Gregus Glutathione-Dependent Reduction of Arsenate by Glycogen Phosphorylase A Reaction Coupled to Glycogenolysis Toxicol. Sci., November 1, 2007; 100(1): 36 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gregus and B. Nemeti Glutathione-Dependent Reduction of Arsenate by Glycogen Phosphorylase Responsiveness to Endogenous and Xenobiotic Inhibitors Toxicol. Sci., November 1, 2007; 100(1): 44 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Nemeti, I. Csanaky, and Z. Gregus Effect of an Inactivator of Glyceraldehyde-3-Phosphate Dehydrogenase, a Fortuitous Arsenate Reductase, on Disposition of Arsenate in Rats Toxicol. Sci., March 1, 2006; 90(1): 49 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gregus and B. Nemeti The Glycolytic Enzyme Glyceraldehyde-3-Phosphate Dehydrogenase Works as an Arsenate Reductase in Human Red Blood Cells and Rat Liver Cytosol Toxicol. Sci., June 1, 2005; 85(2): 859 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Nemeti and Z. Gregus Reduction of Arsenate to Arsenite by Human Erythrocyte Lysate and Rat Liver Cytosol - Characterization of a Glutathione- and NAD-Dependent Arsenate Reduction Linked to Glycolysis Toxicol. Sci., June 1, 2005; 85(2): 847 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsuchiya, T. Tanaka-Kagawa, H. Jinno, H. Tokunaga, K. Sakimoto, M. Ando, and M. Umeda Inorganic Arsenic Compounds and Methylated Metabolites Induce Morphological Transformation in Two-Stage BALB/c 3T3 Cell Assay and Inhibit Metabolic Cooperation in V79 Cell Assay Toxicol. Sci., April 1, 2005; 84(2): 344 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cui, Y. Kobayashi, T. Hayakawa, and S. Hirano Arsenic Speciation in Bile and Urine Following Oral and Intravenous Exposure to Inorganic and Organic Arsenics in Rats Toxicol. Sci., December 1, 2004; 82(2): 478 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Nemeti and Z. Gregus Glutathione-Dependent Reduction of Arsenate in Human Erythrocytes--a Process Independent of Purine Nucleoside Phosphorylase Toxicol. Sci., December 1, 2004; 82(2): 419 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Pires Das Neves, F. Carvalho, M. Carvalho, E. Fernandes, E. Soares, M. D. L. Bastos, and M. D. L. Pereira Protective Activity of Hesperidin and Lipoic Acid Against Sodium Arsenite Acute Toxicity in Mice Toxicol Pathol, August 1, 2004; 32(5): 527 - 535. [Abstract] [PDF]
|
|
|
|
|
|
B. Nemeti, I. Csanaky, and Z. Gregus Arsenate Reduction in Human Erythrocytes and Rats--Testing the Role of Purine Nucleoside Phosphorylase Toxicol. Sci., July 1, 2003; 74(1): 22 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Waalkes and J. Liu Purine Nucleoside Phosphorylase: A Fortuitous Cytosolic Arsenate Reductase? Toxicol. Sci., November 1, 2002; 70(1): 1 - 3. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Nemeti and Z. Gregus Reduction of Arsenate to Arsenite in Hepatic Cytosol Toxicol. Sci., November 1, 2002; 70(1): 4 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gregus and B. Nemeti Purine Nucleoside Phosphorylase as a Cytosolic Arsenate Reductase Toxicol. Sci., November 1, 2002; 70(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Csanaky and Z. Gregus Effect of Phosphate Transporter and Methylation Inhibitor Drugs on the Disposition of Arsenate and Arsenite in Rats Toxicol. Sci., September 1, 2001; 63(1): 29 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gregus, A. Gyurasics, and I. Csanaky Effects of Arsenic-, Platinum-, and Gold-Containing Drugs on the Disposition of Exogenous Selenium in Rats Toxicol. Sci., September 1, 2000; 57(1): 22 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Kala, M. W. Neely, G. Kala, C. I. Prater, D. W. Atwood, J. S. Rice, and M. W. Lieberman The MRP2/cMOAT Transporter and Arsenic-Glutathione Complex Formation Are Required for Biliary Excretion of Arsenic J. Biol. Chem., October 20, 2000; 275(43): 33404 - 33408. [Abstract] [Full Text] [PDF]
|
|